Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.

Nature
Duane A MitchellJohn H Sampson

Abstract

After stimulation, dendritic cells (DCs) mature and migrate to draining lymph nodes to induce immune responses. As such, autologous DCs generated ex vivo have been pulsed with tumour antigens and injected back into patients as immunotherapy. While DC vaccines have shown limited promise in the treatment of patients with advanced cancers including glioblastoma, the factors dictating DC vaccine efficacy remain poorly understood. Here we show that pre-conditioning the vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumour-antigen-specific DCs. To assess the effect of vaccine site pre-conditioning in humans, we randomized patients with glioblastoma to pre-conditioning with either mature DCs or Td unilaterally before bilateral vaccination with DCs pulsed with Cytomegalovirus phosphoprotein 65 (pp65) RNA. We and other laboratories have shown that pp65 is expressed in more than 90% of glioblastoma specimens but not in surrounding normal brain, providing an unparalleled opportunity to subvert this viral protein as a tumour-specific target. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, T...Continue Reading

Associated Clinical Trials

References

Aug 20, 2003·The Journal of Experimental Medicine·Alfonso MartIn-FontechaFederica Sallusto
Feb 5, 2004·Journal of the National Cancer Institute·Yanyun ZhangKouji Matsushima
Aug 10, 2004·Nature Biotechnology·Gregory A DanielsRichard G Vile
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Linda M LiauMichael D Roth
Sep 28, 2007·Nature·Ralph M Steinman, Jacques Banchereau
Feb 10, 2012·Neuro-oncology·Kristine DziurzynskiUNKNOWN HCMV and Gliomas Symposium
Mar 23, 2012·Nature Reviews. Cancer·Karolina Palucka, Jacques Banchereau
Nov 7, 2012·Current Protocols in Immunology·Smita NairThomas F Tedder

❮ Previous
Next ❯

Citations

Nov 17, 2015·Biochimica Et Biophysica Acta·Peter LudewigAnna M Planas
Sep 8, 2015·Vaccines·Pier-Luigi LolliniElena Quaglino
Feb 28, 2016·Stem Cell Research·Vivian Capilla-GonzalezAlfredo Quiñones-Hinojosa
Jul 30, 2016·Oncoimmunology·Tiffany R HodgesAmy B Heimberger
Sep 5, 2015·Human Vaccines & Immunotherapeutics·Li ZhouQiao Li
Jan 6, 2016·Molecular Therapy. Methods & Clinical Development·Drew R DeBayChris V Bowen
Dec 10, 2015·BMC Medicine·Brett J Theeler, Mark R Gilbert
Nov 13, 2015·Future Oncology·Evidio Domingo-Musibay, Evanthia Galanis
Sep 25, 2015·Current Opinion in Neurology·Tobias WeissPatrick Roth
Mar 12, 2016·Nature Reviews. Cancer·Sjoerd H van der BurgCornelis J M Melief
Mar 12, 2016·Regenerative Medicine·Magdalini Papadaki
Oct 12, 2015·Current Treatment Options in Oncology·Martha R Neagu, David A Reardon
Mar 15, 2016·Immunotherapy·Sherise D FergusonAmy B Heimberger
Mar 24, 2016·International Reviews of Immunology·Ilan VolovitzAttila Tárnok
Nov 26, 2015·Immunotherapy·Anda-Alexandra CalinescuMaria Graciela Castro
Jul 28, 2015·The Journal of Clinical Investigation·Cornelis J M MeliefSjoerd H van der Burg
Dec 3, 2015·EBioMedicine·Marc G JeschkeSaeid Amini-Nik
Jul 17, 2015·Neurosurgery·Adam M Sonabend, Guy M McKhann
Jan 1, 2015·Nature Reviews. Disease Primers·Michael WellerGuido Reifenberger
Apr 25, 2015·Nature Reviews. Drug Discovery·Sarah Seton-Rogers
Mar 13, 2015·Nature·Rachel Lubong Sabado, Nina Bhardwaj
May 14, 2016·Expert Opinion on Investigational Drugs·Verena StaedtkeJohn Laterra
May 26, 2016·Expert Opinion on Emerging Drugs·Rupen DesaiJohn H Sampson
May 27, 2016·CNS Oncology·Tiffany R HodgesAmy B Heimberger
Jun 2, 2016·Human Vaccines & Immunotherapeutics·Jennifer D ElsterKenneth G Lucas
Jul 28, 2016·Infectious Agents and Cancer·Cheng-Te Major LinSteven Jacobson
Sep 14, 2016·Oncoimmunology·Erik LadomerskyDerek A Wainwright
Jun 3, 2016·Expert Review of Anticancer Therapy·Nicole A P LiebermanCourtney A Crane
Jun 18, 2016·Science·Bruce A Sullenger, Smita Nair
Jul 14, 2016·Expert Opinion on Biological Therapy·Neha KamranMaria G Castro
Jul 20, 2016·Expert Opinion on Biological Therapy·Yi Lin, Hideho Okada
Aug 9, 2016·Expert Review of Vaccines·Teilo H Schaller, John H Sampson
Jul 15, 2016·Expert Opinion on Investigational Drugs·Julie J MillerJörg Dietrich
Oct 21, 2016·Oncoimmunology·Sanne DuinkerkenJuan J Garcia-Vallejo
Jul 28, 2016·Cancer Immunology, Immunotherapy : CII·Michael PlattenTheresa Bunse
Oct 18, 2016·Cytotherapy·Rebecca S Abraham, Duane A Mitchell
Oct 16, 2016·Journal of Neuro-oncology·Amanda TivnanJochen H M Prehn

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
biopsy
ELISA
flow cytometry

Clinical Trials Mentioned

NCT00639639

Software Mentioned

FlowJo

Related Concepts

Related Feeds

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.